For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of ...

An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation ...

Stay updated on biotech layoffs in 2026! Each week, we track and analyze industry layoffs, their causes, and their impact.

And then biotech does what biotech always does. It reminds you that in this corner of the market, the business is not the ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

Shares Biotechnology ETF (IBB) is a BUY: large-cap biotech stability, M&A and AI catalysts, and 2026 upside. Read the full analysis here.

Americans spent more than $700 billion on prescription medicines last year. However, many of them remain worried about the safety of their medications.

Healthcare stocks rebounded in 2025. These three healthcare growth stocks offer exposure to innovation beyond traditional ...